Triple-negative breast cancer (TNBC), which is defined by the lack of expression of estrogen receptor (ER) and progesterone receptor (PR) and absence of HER2 overexpression and/or gene amplification, accounts for 15% of all breast cancers in the United States. This evidence concerns the gene ESR1 and breast carcinoma.